That is a tremendous fall-back position which reduces risk dramatically for K  but I think Dr M, Leo, and most others who have been in on all the preclinicals and saw the actual data will be dumbfounded if Kevetrin doesn't perform brilliantly throughout the rest of the trials and proves to be quite effective as a stand alone treatment.  I recognize the ability for it to combine in a myriad of other drug cocktails and that IMO makes it almost a dual product;  stand alone and as a facilitator for all other cancer fighting agents.  If any investor can't see the strength of likelihood for success of this product I would have to label them as very mentally challenged or entirely too conservative for the biotech industry as a means of investment.